Kuehn Law, PLLC is investigating whether certain officers and directors of Arcus Biosciences, Inc. breached their fiduciary duties through potential self-dealing. The investigation could lead to shareholder damages and corporate governance reforms. Long-term shareholders are encouraged to contact the law firm for a free consultation, as there may be limited time to enforce their rights. This legal action highlights concerns about management accountability and shareholder protection at Arcus Biosciences.
South Korea's Upbit exchange added four new altcoins—ETHGas (GWEI), Biconomy (BICO), Bubblemaps (BMT), and Nillion (NIL)—with trading pairs in BTC and USDT. ETHGas saw the biggest immediate price jump of about 11%, while the others rose over 7%. Trad...
Tekcapital's portfolio company Guident has signed a 36-month agreement with Coastal Waste & Recycling to deploy its WatchBot autonomous inspection robots and AI software across more than 40 Coastal locations. The system will conduct facility patrols,...
Corcept Therapeutics is rated Strong Buy with price targets of $163 in one year and $222 in two years, driven by rapid revenue and margin growth. The company’s new drug Lifyorli is launching quickly for platinum-resistant ovarian cancer, and Korlym c...
Pop Mart's shares dropped more than 4% after it reported first-half revenue of 17.17 billion yuan, up 23.8% year-over-year but below expectations due to declines in Asia Pacific (excluding China) and the Americas. Revenue in China grew 47.3%, but sal...
Strategy holds 840,447 Bitcoin with an average acquisition cost of $75,385 per coin. On August 21, Bitcoin's price briefly climbed above this cost during an 8.5% daily rally, generating an estimated unrealized gain of about $192 million before prices...
